Tranexamic acid in COVID-19 pneumonia
Hayder M. Al-kuraishy1, Ali I. Al-Gareeb1, Natália Cruz-Martins2,3,4,*, Gaber El-Saber Batiha5,*
1Department of clinical pharmacology and medicine, College of Medicine, Al-Mustansiriya University; Hayderm36@yahoo.com (H.M.A.-K.); Dr.alialgareeb78@yahoo.com (A.I.A.-G.)
2Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
3Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal
4Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, 4200-135 Porto, Portugal
5Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt; gaberbatiha@gmail.com
Corresponding authors: ncmartins@med.up.pt (N.C.-M.); gaberbatiha@gmail.com (G.E.-S.B.)